구조모아 (StructureMoa)항암 chemical structure spider web
방문프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | semaglutide (Ozempic / Wegovy, GLP-1, Wegovy, NN9535) Novo Nordisk·GLP-1 receptor 410 trials·t½ 168 days |
|---|---|
Overview Program | Ozempic / Wegovy (semaglutide) |
Overview Company | Novo Nordisk |
Overview Modality | ANTIBODY |
Overview Target | GLP-1 receptor |
Overview Indication | Type 2 diabetes, chronic weight management, CV risk reduction (T2D) |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Weekly SC (Ozempic/Wegovy) and oral form (Rybelsus) |
Positioning Known limitation | GI intolerance leading to discontinuation; plateau after dose titration |
Positioning Development positioning | GLP-1 class anchor vs tirzepatide dual agonist |
MoA Mechanism | Semaglutide activates GLP-1 receptors on pancreatic beta cells (glucose-dependent insulin secretion), suppresses glucagon, slows gastric emptying, and reduces appetite via central pathways. |
MoA Biomarker | HbA1c, body weight, SELECT CV outcomes in obesity with CVD. |
PK/PD Half-life | 168 days |
PK/PD Species | Rat, HbA1c ↓1.5–1.8%, weight ↓~15% at 68 wk (STEP-1) |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | PK |
Toxicology Species | NHP, Mouse, Rat |
Toxicology Animal (cat.) | NHP |
Toxicology Major finding | Thyroid C-cell tumors in rodents (class warning); GI AEs in clinic |
Toxicology CRS | N/A |
Clinical Safety signal | Thyroid C-cell tumors in rodents (class warning); GI AEs in clinic |
Clinical Selected reported efficacy | Weight 1.01% |
Clinical Weight % | weight loss is essential but difficult |
Clinical Result source | ClinicalTrials.gov NCT03480022 |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT03480022 |
Preclinical Animal (cat.) | Mouse |
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | semaglutide (Ozempic / Wegovy, GLP-1, Wegovy, NN9535) Novo Nordisk·GLP-1 receptor 410 trials·t½ 168 days |
|---|---|
Overview Program | Ozempic / Wegovy (semaglutide) |
Overview Company | Novo Nordisk |
Overview Modality | ANTIBODY |
Overview Target | GLP-1 receptor |
Overview Indication | Type 2 diabetes, chronic weight management, CV risk reduction (T2D) |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Weekly SC (Ozempic/Wegovy) and oral form (Rybelsus) |
Positioning Known limitation | GI intolerance leading to discontinuation; plateau after dose titration |
Positioning Development positioning | GLP-1 class anchor vs tirzepatide dual agonist |
MoA Mechanism | Semaglutide activates GLP-1 receptors on pancreatic beta cells (glucose-dependent insulin secretion), suppresses glucagon, slows gastric emptying, and reduces appetite via central pathways. |
MoA Biomarker | HbA1c, body weight, SELECT CV outcomes in obesity with CVD. |
PK/PD Half-life | 168 days |
PK/PD Species | Rat, HbA1c ↓1.5–1.8%, weight ↓~15% at 68 wk (STEP-1) |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | PK |
Toxicology Species | NHP, Mouse, Rat |
Toxicology Animal (cat.) | NHP |
Toxicology Major finding | Thyroid C-cell tumors in rodents (class warning); GI AEs in clinic |
Toxicology CRS | N/A |
Clinical Safety signal | Thyroid C-cell tumors in rodents (class warning); GI AEs in clinic |
Clinical Selected reported efficacy | Weight 1.01% |
Clinical Weight % | weight loss is essential but difficult |
Clinical Result source | ClinicalTrials.gov NCT03480022 |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT03480022 |
Preclinical Animal (cat.) | Mouse |
추천 비교
추천 비교